Stroke is a leading cause of death worldwide. It is often followed by complications, especially infections, which occur in 30% of stroke patients and are strongly associated with unfavorable outcomes and high mortality[@b1][@b2][@b3]. Pneumonia and urinary tract infections were the most common types of post-stroke infections[@b2]. Furthermore, post-stroke pneumonia occurs in 10% of patients after an acute stroke, about half of which occur within the first 48 h after stroke onset[@b4][@b5]. Moreover, post-stroke pneumonia is associated with high mortality[@b6]. These results indicate that preventive anti-infection strategies may be beneficial for patients who have suffered a stroke.

Previous studies on the preventive use of antimicrobials in patients with acute stroke found conflicting results. Recently, a meta-analysis including 506 patients concluded that prophylactic antibiotics treatment after the onset of stroke significantly reduced the infection rate without major adverse effects, but had no effect on the mortality rate. Moreover, its effectiveness in reducing post-stroke pneumonia was ambiguous[@b7]. Further, existing guidelines for management of acute stroke state that prophylactic use of antibiotics is not recommended because it has not been proven to be effective[@b8]. Since the previous meta-analysis, there have been more multicenter randomized controlled trials with larger samples. Therefore, we performed this updated meta-analysis to systematically assess the effects of prophylactic antibiotics treatment on post-stroke infections and the occurrence of mortality among adult acute stroke patients. Importantly, we first take a subgroup meta-analysis of the effects of the preventive use of antimicrobials on the rate of post-stroke pneumonia and urinary tract infections.

Results
=======

Characteristics of eligible studies
-----------------------------------

There were 808 records identified using different search strategies in three databases (345 from PubMed, 192 from Embase, and 270 from Web of Knowledge) and 1 record identified by ref. [@b9]. After removing 197 duplications and 591 unrelated records by reading the titles and abstracts, 20 records warranted further screening through full-text reading. After full-text reading, 13 records were excluded including 5 records with insufficient data, 5 comments and 3 reviews. Finally, 7 studies fulfilled the eligibility criteria for inclusion in the primary analysis[@b9][@b10][@b11][@b12][@b13][@b14][@b15]. The study selection diagram is shown in [Fig. 1](#f1){ref-type="fig"}.

The characteristics of the studies included in analysis are listed in [Table 1](#t1){ref-type="table"}. Those studies were published during 1998--2015. Four studies only included ischemic stroke patients[@b9][@b11][@b12][@b13] and three studies included ischemic and hemorrhagic stroke patients[@b10][@b14][@b15]. Six studies were included for infection analysis. There were four studies with sufficient data for analyzing cases of pneumonia and urinary tract infections. The remaining six studies were involved in the analysis of mortality rates. The results of the Jadad Scale showed that four studies had high quality scores and three studies had low quality scores. A risk of bias table for each study is provided in [Supplementary Table S1](#S1){ref-type="supplementary-material"}.

Preventive Antibiotics Treatment at Stroke Onset and Outcomes
-------------------------------------------------------------

Among the seven observational studies, 4261 patients were included. There were six studies used to analyze the effects of preventive antibiotics treatment on post-stroke infections, and one study did not provide efficiency data[@b11]. And the definitions used for infection in all included studies were presented in [Supplementary Table S3](#S1){ref-type="supplementary-material"}. In all, 3831 patients (treatment group: 1926 patients; control group: 1905 patients) were included. The results of our meta-analysis suggested that preventive antibiotics treatment at the time of stroke onset reduced the occurrence of infections in adults with acute stroke (OR = 0.57, 95% CI: 0.38--0.85, *P* = 0.005) ([Fig. 2A](#f2){ref-type="fig"}, [](#t2){ref-type="table"}[Table 3](#t3){ref-type="table"}).

However, among the subgroup analysis, only four studies were used to analyze the effects of preventive antibiotics treatment on post-stroke pneumonia, urinary tract infections and other infections, as the other studies did not report the occurrence rates. Thus, 3894 patients (treatment group: 1952 patients; control group: 1942 patients) were included. In this meta-analysis, we found that prophylactic antibiotics did not reduce the incidence of pneumonia in adult patients with acute stroke (OR = 0.91, 95% CI: 0.73--1.13, *P* = 0.385) ([Fig. 2B](#f2){ref-type="fig"}, [Table 3](#t3){ref-type="table"}) and other infections (OR = 1.00, 95% CI: 0.63--1.60, *P* = 0.996) ([Supplementary Figure S1](#S1){ref-type="supplementary-material"}), but decreased the incidence of urinary tract infections significantly (OR = 0.34, 95% CI: 0.26--0.46, *P* \< 0.001) ([Fig. 2C](#f2){ref-type="fig"}, [Table 3](#t3){ref-type="table"}).

Preventative antibiotics treatment at the time of stroke onset also did not reduce the mortality rate in adults with acute stroke (OR = 0.91, 95% CI: 0.73--1.13, *P* = 0.743) ([Fig. 2D](#f2){ref-type="fig"}, [Table 3](#t3){ref-type="table"}). All of the studies included in this meta-analysis reported the mortality rate, but one study had no deaths in either the treatment group or control group[@b13], so it was excluded, and the remaining studies including 4201 patients were analyzed (treatment group: 2101 patients; control group: 2100 patients). Indeed, as the modified Rankin Scale (mRS) score 0--2 was defined as a good outcome, preventative antibiotics treatment also did not show a benefit on the functional outcome evaluating by mRS score 0--2 (OR = 1.76, 95% CI: 0.86--3.63, *p* = 0.124) ([Fig. 3](#f3){ref-type="fig"} and [Table 3](#t3){ref-type="table"}). Besides, the antibiotic related side effects the outcome of neurological recovery were listed in [Table 2](#t2){ref-type="table"}.

Heterogeneity analysis
----------------------

Obvious between-study heterogeneity was found while estimating the effects of preventive antibiotics treatment on post-stroke infections (*I*^*2*^ = 63.4%, *P* = 0.018) ([Fig. 2A](#f2){ref-type="fig"}, [Table 3](#t3){ref-type="table"}). To explore the between-study heterogeneity, a Galbraith plot was generated to graphically evaluate the sources. One study[@b13] was outside the bounds of the Galbraith plot ([Supplementary Figure S2](#S1){ref-type="supplementary-material"}), which was identified as the primary source of our between-study heterogeneity. Once this study was removed, the heterogeneity effectively decreased (*I*^*2*^ = 46.6%, *P* = 0.112, [Table 3](#t3){ref-type="table"}). Although no obvious heterogeneity was detected again among the remaining studies, the corresponding pooled OR changed little (OR = 0.65, 95% CI: 0.55--0.77, *P* \< 0.001) ([Supplementary Figure S3](#S1){ref-type="supplementary-material"}). Therefore, preventive antibiotics treatment at the time of stroke onset may significantly reduce the risk of infections in adults with acute stroke.

In contrast, among the occurrence rate of post-pneumonia, urinary tract infections and mortality analysis, there was no obvious between-study heterogeneity (*I*^*2*^ = 31.0%, *P* = 0.225; *I*^*2*^ = 0.0%, *P* = 0.826; *I*^*2*^ = 26.2%, *P* = 0.238, respectively) ([Fig. 2B--D](#f2){ref-type="fig"}).

Sensitivity analysis and publication bias
-----------------------------------------

Each study was removed sequentially to verify the effect of each individual study on our on our results. No obvious changes were found after excluding any study. Therefore, our results were reliable (data not shown). Both Egger's and Begg's methods were applied to explore the publication bias in our meta-analysis. There was no significant publication bias among the occurrence rate of post-stroke infections, post-stroke pneumonia, urinary tract infections, mortality analysis in our study (Begg's test: *P* = 0.348, *P* = 0.734, *P* = 0.497, *P* = 1.000 respectively). The funnel plots are shown in [Supplementary Figure S5](#S1){ref-type="supplementary-material"}.

Discussion
==========

In this meta-analysis including data from 4261 patients, significant associations were found between preventive antibiotics treatment at stroke onset and post-stroke infections. We also found that the use of preventive antibiotics was not associated with a significant reduction in mortality rate. Compared with previous meta-analyses[@b7][@b16], this meta-analysis contained more studies and the sample size was more than 8 times larger. Further, among our subgroups analysis we first found that preventive antibiotics treatment could not decrease the occurrence rate of post-stroke pneumonia, even though showed an effect on reducing urinary tract infections. We have found that no major side-effects were reported, although 2 patients developed exanthema or elevated liver enzymes with mezlocillin plus sulbactam treatment[@b13].

Post-stroke infections were the most common complications of the acute phase after stroke, and most infections occurred within three days of hospital admission[@b17]. 30% of post-stroke patients experienced subsequent infection, including pneumonia and urinary tract infections that each occured in 10% of patients[@b2]. As the studies have been performed in general wards as well as ICU's, pneumonia was mostly diagnosed within the first day following a stroke[@b18][@b19][@b20]. However, we found prophylactic antibiotic treatment did not decrease the occurrence rate of post-stroke pneumonia, although it was associated with a significant reduction in post-stroke infections and urinary tract infections. The most likely explanation is that post-stroke pneumonia may be a respiratory syndrome resulting from multiple factors, including medical complications and complex bacterial, chemical, and immunological causes that might not be preventable with antibiotics alone[@b14][@b21]. For example, acute stroke may lead to stroke-induced immunodepression by the cholinergic pathway, reducing lymphocyte count and delaying the recovery of T-lymphocyte loss, which may promote stroke patients developing post-stroke pneumonia[@b22][@b23][@b24]. More importantly, other existing preventive measures such as positioning, regular suction, swallowing techniques and modified diets may also be essential for patients with suspected post-stroke pneumonia in specialist stroke units[@b25]. For example, dysphagia screening, malnutrition, recumbency and tube feeding were associated with high risks for stroke patients developing pneumonia[@b26][@b27]. However, some studies found that a standardized multidisciplinary protocolized feeding tube placement has a beneficial role in preventing aspiration pneumonia in mildly or moderately disabled post-stroke patients[@b28][@b29]. Those may indicate that the stroke patient's clinical conditions have a close link with pneumonia. Previous studies also found that patients with a higher stroke severity or lower levels of consciousness showed higher infection rates, in particular for pneumonia[@b30][@b31]. Further, the lesion location of a stroke also influenced the occurrence rate of post-stroke pneumonia. An ischemic lesion occurring in the anterior middle cerebral artery cortex has a higher susceptibility to stroke-associated infections[@b32][@b33]. Therefore, more normative cohort studies may elucidate why prophylactic antibiotics treatment could decrease the occurrence rate of post-stroke infections but have no effect on pneumonia.

In agreement with previous studies[@b7][@b16], we also found that preventive antibiotics treatment at stroke onset could reduce the occurrence rate of post-stroke infections, which were associated with decreased functional outcome. Thus, the question arises as to why preventive antibiotics treatment did have a significant effect on post-stroke infections but no influence on the mortality rate. The explanation may be that infections could be just a marker or bystander of poor functional outcome, and preventive antibiotics treatment might not change the course of disease. On the other hand, as the modified Rankin Scale (mRS) score 0--2 was defined as a good outcome, out of four studies that reported the effects of preventive antibiotics treatment with a mRS score, one study had invalid data[@b13]. We also found that preventive antibiotics treatment showed no significant association with functional outcome. Thus, the other explanation may be that the type and dose of antibiotics were varied among the different studies. Indeed, some antibiotics showed neuroprotective properties in animal models of stroke, including minocycline and ceftriaxone[@b34][@b35]. Among ischemic stroke patients who received oral minocycline for 5 days, male but not female patients had significantly better neurological outcomes on day 90 than male patients[@b34]. Thus, in further studies, the male and female patients should be analyzed separately.

During analysis of the association between preventive antibiotics treatment and post-stroke infections, obvious heterogeneity was found. We noted that one study contributed to the heterogeneity across all included studies, which potentially confounded the analyses[@b13]. When we removed this study, the corresponding pooled RR value with very few changes was stable and reliable. The reason may be that this study excluded patients with a life expectancy of fewer than 90 days, possibly leaving only the less severely affected patients and, thus, overestimating the effect of preventive antibiotic therapy. Importantly, previous studies have confirmed that stroke severity was a risk factor for post-stroke infection[@b36]. Moreover, some potential bias had an important influence on the analysis, including publication bias and selection bias, but little evidence of publication bias was observed. Furthermore, only eligible studies published in English were included in this meta-analysis, so additional research in other populations is warranted to support generalization of the findings.

We acknowledge that there were several limitations in our study. First, relatively few studies were included in the meta-analysis, which restrict the strength and quality of the evidence. Only two studies used a randomized and double-blind design[@b10][@b12], and other studies would increase the risk of bias and then may diminished the reliability of our results. Second, the diagnosis standard of infections were different among the studies included. Third, the inclusion criteria of antibiotic types were various among all included studies. It is possible that different antibiotic type may have varied beneficial effect against post-stroke infection. However, what a pity, all included studies did not present available data to conduct subgroup analysis by these factors (sex, stroke severity, and antibiotics type). Besides, even though we found some benefit of prophylactic antibiotic in urinary tract infection, we can't identify what subgroup (e.g high NIHSS or elderly or antibiotic class) is better because those studies did not conduct subgroup analysis on urinary tract infection. The information regarding the cause of infections and death was unavailable, as was any individual patient data that might be used to establish the influence of different antibiotics treatments, dose--response relationships, or associations between sex and outcome. Lastly, there are no persuasive evidences to confirm whether antibiotics prophylaxis is good for stroke patients or not. Thus, larger randomized controlled trials are required.

Methods
=======

This meta-analysis and systematic review protocol has been follow the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement.

Search strategy and selection criteria
--------------------------------------

All published articles were searched in the PubMed, Embase, and Web of Knowledge databases up through March 11^th^, 2016. Key words were identified as follows: "stroke", "cerebral infarction", "brain infarction", "cerebrovascular disease", "cerebral hemorrhage", "intracranial hemorrhage" or "cerebrovascular disorder"; and "infection", "inflammation", "fever", "bacteraemia", "sepsis", or "pneumonia"; and "antimicrobial agents", "antibiotics" or "prophylactic antibiotics"; and "prophylaxis" or "prevention". The updated literature search, data extraction, and quality assessments were conducted independently by two authors (L.L., X.-Y. X.). All articles were retrieved and their references were checked to avoid missing other relevant articles. If data were not included in the original articles, we contacted the authors to obtain them.

Inclusion and Exclusion Criteria
--------------------------------

The inclusion criteria were as follows: (1) studies evaluating the effects of preventive antibiotics treatment in adult acute stroke patients (predefined as age 16 years or older); (2) randomized controlled trials were eligible for inclusion; and (3) The effect estimates of studies could be extracted or calculated from the available data. The exclusion criteria were as follows: (1) studies with insufficient data to calculate or extract effect estimates and (2) case reports, reviews, comments, abstracts or animal studies.

Data Extraction
---------------

Two independent researchers (L.L., X.-Y. X.) conducted data extraction to ensure the reliability of the results. Disagreement was resolved by discussion. The information of studies meeting the inclusion criteria were extracted using a standardized extraction form. Relevant information included the first author's name, publication year, inclusion criteria, exclusion criteria, intervention, outcomes, the numbers of cases and controls, the infection rate, urinary tract infections and pneumonia rate, other infections rate, the rate of mortality, mRS score, antibiotic related side effects and the Jadad Score.

Assessment of Study Quality and Statistical Analysis
----------------------------------------------------

The quality of the studies was evaluated by two independent reviewers (L.L., X.Y.X.) according to the Jadad Scale, which contains three dimensions: randomization, blinding and withdrawals for case-control studies. The Jadad Scale is a validated 5-point scale assessing the following criteria: (1) whether randomized (yes = 1 point, no = 0); (2) whether randomization was described appropriately (yes = 1 point, no = 0); (3) whether double-blind (yes = 1 point, no = 0); (4) whether the double-blinding was described appropriately (yes = 1 point, no = 0); and (5) whether the dropouts and withdrawals were described (yes = 1 point, no = 0). The quality score ranges from 0 to 5 points, where 0--2 points is defined as a low-quality report study and a high quality study score is at least 3 points.

For all included studies, we (L.L and X.Y.X.) independently assessed the risk of bias for the following items: adequacy of sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessment; Incomplete outcome data; selective reporting; and other sources of bias. We have categorized these judgments as 'low', 'high', or 'unclear' risk of bias[@b37].

For each study, unadjusted odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were derived from patient numbers with each outcome categorized by antibiotics treatment. A Z test was conducted to assess the statistical significance of pooled ORs and 95% Cis. I-squared (I^2^) statistic and Chi-square-based Q-tests were used to investigate the heterogeneity across studies[@b38]. The selection of effects models according to our heterogeneity test was as follows: *P* \> 0.10 for the Q test and I^2^ values less than 50% suggested no obvious heterogeneity across studies and a fixed (Mantel-Haenszel) effects model was applied; otherwise, a random (DerSimonian-Laird) effects model was used[@b39]. In addition, Galbraith plots were used to further explore the source of between-study heterogeneity. We also performed sensitivity analysis by removing each included study in sequence to assess the stability of our results. Publication bias was evaluated via a funnel plot using both Egger's[@b40] and Begg's[@b41] methods. Statistical significance was defined as a P-value \<0.05. All statistical analyses were performed using STATA 12.0 software (Stata Corp, College Station, TX, USA).
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###### Characteristics of the studies included in the meta-analysis.

  Author (publication year)                                    Inclusion criteria                                                                                                               Exclusion Criteria                                                                                                                         Intervention                                                                                                                Outcomes                                                                              Inclusion NIHSS Treatment vs Control          Sample size   Infections Treatment vs Control   Pneumonia Treatment vs Control   Urinary tract infections Treatment vs Control   Mortality Treatment vs Control   Jadad Score
  --------------------------- ------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------- ------------- --------------------------------- -------------------------------- ----------------------------------------------- -------------------------------- -------------
  De Falco *et al*.[@b9]                                Ischemic stroke within 12 hours                                                                                                                 NA                                                                                                                          Penicillin intramuscularly                                                                           Infectious complications, case fatality, functional outcome (BI, CNS)                                           CNS score: Mean (SD), 4.5 (2.3) vs 4.1 (2.1)         38/42               4/30 vs 8/30                           NA                                      NA                                  4/38 vs 7/42                 2
  Chamorro *et al*.[@b10]                     Stroke within 24 hours; age \>18 y; NIHSS \>score 4                   Infection \<3 months; T \>37. 7 °C; allergy to fluoroquinolones; epilepsy; seizures; serum creatinine \>2.5 mg/dL, antibiotics user; immunosuppressants therapy \<3 months        Intravenous 500 mg/100 mL levofloxacin for 3 days, started within 24 h of stroke onset                          Early infection (within 7 days), mortality, favorable outcome on day 90 (mRS \<2, NIHSS \<2, BI 95 or 100)                       Median (interquartile), 14 (7--19) vs 11 (7--18)       67/69              11/67 vs 13/69                          NA                                      NA                                 16/67 vs 9/69                 5
  Lampl *et al*.[@b11]                 Ischemic stroke within 6 to 24 hours; age \>18 y; NIHSS score \>5              Hemorrhagic stroke; other disease; pre-existing neurologic disability; tetracycline allergic; renal failure; pre-existing infectious disease; swallowing difficulties               Orally minocycline 200 mg/d for 5 days, started within 6--24 h of stroke onset                                                        NIHSS on day 90; NIHSS, mRS, BI, death on day 7, 30, 90                                                       Mean (SD), 7.6 (3.8) vs 7.5 (3.2)               74/77                    NA                                NA                                      NA                                  5/74 vs 9/77                 2
  Harms *et al*.[@b12]         Ischemic stroke within 9 to 36 hours; aged ≥18 y; NIHSS score ≥11 in MCA territory                        Hemorrhagic stroke; infections; antibiotics therapy \<24 h; contraindications against moxifloxacin; immunosuppressant treatment                                 Intravenous 400 mg/d moxifloxacin for 5d, started within 36 h of stroke of onset           Infection rate on 11th day, bacterial spectrum, moxifloxacin resistance, body temperature, CRP, survival and functional outcome (BI) on day 180   Median (interquartile), 17 (12--21) vs 15 (12--25)      39/40               6/39 vs 13/40                     3/39 vs 8/40                            3/39 vs 5/40                             1/39 vs 3/40                 5
  Schwarz *et al*.[@b13]                  Ischemic stroke within 24 hours; age \>18 y; NIHSS score \>5                                    Hemorrhagic stroke; infections; renal insufficiency; penicillin or sulbactam allergic; immunosuppressant treatment; pregnancy                          Intravenous mezlocillin 6 g/d plus sulbactam 1 g/d for 4 d, started within 24 h of stroke onset                                                      mRS on day 90, infection, daily temperature                                                      Median (interquartile), 17 (8--28) vs 15 (5--27)       30/30              15/30 vs 27/30                     5/30 vs 7/30                            8/30 vs 18/30                            0/30 vs 0/30                 2
  Westendorp *et al*.[@b14]                    Stroke within 24 hours; aged ≥18 y; NIHSS score ≥1                                               Infections; antibiotics therapy \<24 h; pregnancy; penicillin or cephalosporins allergic; subarachnoid hemorrhage;                                         Intravenous 2 g/d ceftriaxone for 4d, started within 24 h of stroke of onset                                                                  mRS on 3 months, mortality, infection                                                           Median (interquartile), 5 (3--9) vs 5 (3--9)       1268/1270         130/1268 vs 218/1270               71/1268 vs 88/1270                      46/1268 vs 127/1270                     131/1268 vs 136/1270             3
  Kalra *et al*.[@b15]                       Stroke within 48 hours and with dysphagia; aged \>18 y                                                       Allergic to antibiotics; infections; preexisting dysphagia; pyrexia; pregnancy; imminent death                                         amoxicillin or co-amoxiclav, plus clarithromycin for 7 d, started within 24 h of stroke of onset                               Post-stroke pneumonia and mortality on day 14 and 90, mRS \<2 on day 90, adverse events                                Median (interquartile), 15 (9--20) vs 14 (9--20)      615/602           123/615 vs 136/602                101/615 vs 91/602                        15/615 vs 39/602                        184/615 vs 158/602              4

NA, not available; BI, Barthel Index; CNS, central nervous system; SD, standard deviation; NIHSS, National Institute of Health Stroke Scale.

T, temperature; mRS, modified Rankin Score; MCA, middle cerebral artery; CRP, C-reactive protein.

###### The outcome of antibiotic related side effects and the outcome of neurological recovery.

  **Author (publication year)**    **Diarrhea Treatment vs Control**   **Multi-drug resistant infection Treatment vs Control**   **mRS score 0--2 Treatment vs Control**
  ------------------------------- ----------------------------------- --------------------------------------------------------- -----------------------------------------
  De Falco *et al*.[@b9]                          NA                                             NA                                                NA
  Chamorro *et al*.[@b10]                         NA                                             NA                                                NA
  Lampl *et al*.[@b11]                            NA                                             NA                                          67/74 vs 35/77
  Harms *et al*.[@b12]                       2/40 vs 2/39                                        NA                                                NA
  Schwarz *et al*.[@b13]                          NA                                             NA                                           0/30 vs 0/ 30
  Westendorp *et al*.[@b14]                2/1242 vs 0/1270                               6/1242 vs 5/1270                                781/1268 vs 763/1270
  Kalra *et al*.[@b15]                      2/615 vs 4/602                                11/615 vs 14/602                                 109/595 vs 121/586

NA, not available.

###### Summary of meta-analysis results.

  Groups                           Studies   Test of association   Heterogeneity                                
  ------------------------------- --------- --------------------- --------------- ---- ------ ------- --------- --------
  Infections                          6      0.57\[0.39--0.82\]        0.003       RE    3     11.77    0.038    57.50%
  Infections (except one study)       5      0.63\[0.53--0.75\]       \<0.001      FE   5.18   5.81     0.214    31.1%,
  Pneumonia                           4      0.91\[0.73--1.13\]        0.385       FE   0.87   4.35     0.225    31.0%,
  Urinary tract infections            4      0.34\[0.26--0.46\]       \<0.001      FE   7.37    0.9     0.826    0.00%
  mRS (0--2)                          4      1.76\[0.86--3.63\]        0.124       RE   1.54   29.08   \<0.001   93.1%

RE, random effects; FE, fixed effects; OR, odds ratio; CI, confidence interval.
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